Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 1;34(9):1035-1045.
doi: 10.1097/CAD.0000000000001480. Epub 2022 Dec 19.

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models

Mahmoud El Shemerly  1 , Elisa Zanini  1 , Marc Lecoultre  2 , Paul R Walker  2 , Laurenz Kellenberger  1 , Heidi A Lane  1 , Paul M J McSheehy  1
Affiliations

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models

Mahmoud El Shemerly et al. Anticancer Drugs. .

Abstract

Derazantinib (DZB) is an inhibitor of the fibroblast growth factor receptors 1-3 (FGFRi) with similar potency against colony-stimulating factor receptor-1 (CSF1R), a protein important in the recruitment and function of tumor-associated macrophages. DZB inhibited pCSF1R in the macrophage cell line RAW264.7, and tumor cells GDM-1 and DEL, and had the same potency in HeLa cells transiently over-expressing FGFR2. DZB exhibited similar potency against pCSF1R expressed by isolated murine macrophages, but as in the cell lines, specific FGFRi were without significant CSF1R activity. DZB inhibited growth of three tumor xenograft models with reported expression or amplification of CSF1R, whereas the specific FGFRi, pemigatinib, had no efficacy. In the FGFR-driven syngeneic breast tumor-model, 4T1, DZB was highly efficacious causing tumor stasis. A murine PD-L1 antibody was without efficacy in this model, but combined with DZB, increased efficacy against the primary tumor and further reduced liver, spine and lung metastases. Immunohistochemistry of primary 4T1 tumors showed that the combination favored an antitumor immune infiltrate by strongly increasing cytotoxic T, natural killer and T-helper cells. Similar modulation of the tumor microenvironment was observed in an FGFR-insensitive syngeneic bladder model, MBT-2. These data confirm CSF1R as an important oncology target for DZB and provide mechanistic insight for the ongoing clinical trials, in which DZB is combined with the PD-L1 antibody, atezolizumab.

PubMed Disclaimer

References

    1. Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nature 2017; 17:318–332.
    1. Hall T, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre J-M, et al. Preclinical activity of derazantinib, a novel inhibitor targeting FGFR dysregulation. PLoS One 2016; 11:e0162594.
    1. Javle MM, Abou-Alfa GK, Macarulla T, Personeni N, Bergamo F, Malka D, et al. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01. J Clin Oncol 2022; 40(Suppl 4):427.
    1. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21:671–684.
    1. McSheehy PM, Boult J, Robinson SP, Bachmann F, El-Shemerly M, Kellenberger L, et al. Derazantinib, an oral fibroblast growth factor receptor inhibitor, in Phase 2 clinical development, shows anti-angiogenic activity in pre-clinical models. Eur J Cancer 2020; 138:S25–S26.

Publication types